Galapagos NV reported cash and cash equivalents of €1.3 billion on 30 June in a first-half year report that also highlighted an ambitious research and development programme for small molecules targeting inflammatory indications and cystic fibrosis.
Galapagos NV reported cash and cash equivalents of €1.3 billion on 30 June in a first-half year report that also highlighted an ambitious research and development programme for small molecules targeting inflammatory indications and cystic fibrosis.